BIODESIX, INC. Proceeds from Notes Payable
BIODESIX, INC. (BDSX) reported Proceeds from Notes Payable of $3.08 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2021-03-16
- BIODESIX, INC. proceeds from notes payable for the quarter ending 2020-12-31 was $0.00.
- BIODESIX, INC. proceeds from notes payable for fiscal 2020 was $3.08M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $3.08M 10-K · filed 2021-03-16 | |
| 2020-09-30 | $3.08M 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |